Apoptosis in cardiac disease: from basics to clinics--an editorial commentary.
Paul
M
M
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D053148:Caspase 3; D061945:Caspase Inhibitors; D020169:Caspases / Q000378:metabolism; D003546:Cysteine Endopeptidases / Q000378:metabolism; D016207:Cytokines / Q000502:physiology; D053938:DNA Fragmentation / Q000187:drug effects; D006321:Heart / Q000502:physiology / Q000503:physiopathology; D006331:Heart Diseases / Q000150:complications / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000503:physiopathology; D020287:In Situ Nick-End Labeling; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D018377:Neurotransmitter Agents / Q000502:physiology; D011412:Propanolamines / Q000627:therapeutic use; D015398:Signal Transduction; D020257:Ventricular Remodeling / Q000502:physiology; D048051:p38 Mitogen-Activated Protein Kinases
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D002227:Carbazoles; D061945:Caspase Inhibitors; D016207:Cytokines; D018377:Neurotransmitter Agents; D011412:Propanolamines; D000077261:Carvedilol; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; D003546:Cysteine Endopeptidases